Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer
- PMID: 34655352
- DOI: 10.1245/s10434-021-10868-4
Access Denied: Inequities in Clinical Trial Enrollment for Pancreatic Cancer
Abstract
Background: The influence of social determinants of health (SDH) on participation in clinical trials for pancreatic cancer is not well understood. In this study, we describe trends and identify disparities in pancreatic cancer clinical trial enrollment.
Patients and methods: This is a retrospective study of stage I-IV pancreatic cancer patients in the 2004-2016 National Cancer Database. Cohort was stratified into those enrolled in clinical trials during first course of treatment versus not enrolled. Bivariate analysis and logistic regression were used to understand the relationship between SDH and clinical trial participation.
Results: A total of 1127 patients (0.4%) enrolled in clinical trials versus 301,340 (99.6%) did not enroll. Enrollment increased over the study period (p < 0.001), but not for Black patients or patients on Medicaid. The majority enrolled had metastatic disease (65.8%). On multivariate analysis, in addition to year of diagnosis (p < 0.001), stage (p < 0.001), and Charlson score (p < 0.001), increasing age [odds ratio (OR) 0.96, 95% confidence interval (CI) 0.96-0.97], non-white race (OR 0.54, CI 0.44-0.66), living in the South (OR 0.42, CI 0.35-0.51), and Medicaid, lack of insurance, or unknown insurance (0.41, CI 0.31-0.53) were predictors of lack of participation. Conversely, treatment at an academic center (OR 6.36, CI 5.4-7.4) and higher neighborhood education predicted enrollment (OR 2.0, CI 1.55-2.67 for < 7% with no high school degree versus > 21%).
Discussion: Age, race, insurance, and geography are barriers to clinical trial enrollment for pancreatic cancer patients. While overall enrollment increased, Black patients and patients on Medicaid remain underrepresented. After adjusting for cancer-specific factors, SDH are still associated with clinical trial enrollment, suggesting need for targeted interventions.
Keywords: Clinical trials; Health disparities; Pancreatic cancer; Social determinants of health.
© 2021. Society of Surgical Oncology.
References
-
- Thornton RL, Glover CM, Cené CW, Glik DC, Henderson JA, Williams DR. Evaluating strategies for reducing health disparities by addressing the social determinants of health. Health Affairs (Project Hope). 2016;35(8):1416-23. doi: https://doi.org/10.1377/hlthaff.2015.1357.
-
- Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst. 2007;99(18):1384-94. doi: https://doi.org/10.1093/jnci/djm127.
-
- Kurani SS, McCoy RG, Lampman MA, et al. Association of neighborhood measures of social determinants of health with breast, cervical, and colorectal cancer screening rates in the US Midwest. JAMA Netw Open. 2020;3(3):e200618. doi: https://doi.org/10.1001/jamanetworkopen.2020.0618.
-
- Hernandez ND, Durant R, Lisovicz N, et al. African American cancer survivors' perspectives on cancer clinical trial participation in a safety-net hospital: considering the role of the social determinants of health. J Cancer Educ. 2021;doi: https://doi.org/10.1007/s13187-021-01994-4.
-
- Health NIo. NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research. 2001.
MeSH terms
LinkOut - more resources
Full Text Sources